Podcasts about Thermo Fisher Scientific

988: In this episode of Technovation, we feature a panel from the Metis Strategy Summit moderated by Metis Strategy's Co-Head of Executive Networks, Media, and Research Steven Norton, exploring how senior technology executives are aligning AI to their business strategy. Joining the conversation are Ryan Snyder, CIO of Thermo Fisher Scientific; Ramkumar Rayapureddy, CIO of Viatris; and Allen Fazio, CIO of Houlihan Lokey. Together, they share how their organizations are evolving from isolated AI pilots to holistic strategies grounded in business value, robust governance, and relentless data modernization. The panelists discuss the practical realities of establishing clear measurement frameworks, navigating the tension between centralized control and decentralized innovation, and leading cultural change as AI adoption accelerates across regulated and fast-moving industries.

In the latest Clarity podcast, Thomson Reuters' Will Strickland and Jenifer Fernandez are joined by trade expert Ryan Bialas, Director of Global Trade Compliance for Thermo Fisher Scientific, to explore how technology tools and innovative strategies are helping businesses mitigate the impacts of tariffs and how trade professionals can navigate changing tariff policies.

US equity futures are sharply lower, as risk sentiment deteriorated amid escalating Middle East tensions. Asian markets fell broadly, European equities are also trading lower. Israel launched airstrikes on Iranian nuclear and military targets, prompting fears of regional escalation. President Trump said the US was not involved but convened his cabinet; Israel declared a state of emergency and signaled operations may continue for days. Trump reiterated unilateral tariff threats and raised the prospect of 25% auto tariffs. Trade talks with Japan, India, and the EU remain challenging ahead of the G7 summit. US inflation data showed further cooling; jobless claims steady but continuing claims rose to a multi-year high.Companies Mentioned: NVIDIA, Thermo Fisher Scientific, CK Hutchison Holdings, COSCO SHIPPING Holdings, Blackrock

Our guest this week is Rick Bolle of Naperville, IL founding pastor of the newly formed Front Porch Church, father of two and retired businessman. Rick and his wife, Alinda, have been married for 32 years and are the proud parents of two adult children.  Shortly after retiring from Thermo Fisher Scientific in 2022, where he was a Senior Safety Specialist, Rick felt a calling to start or plant Front Porch Church.   Established in 2023, Front Porch Church helps people of all ability find their way back to God.  FPC is specifically designed to welcome individuals with special needs and their families.  Weekly services offer a worship experience that embraces all expressions and all movements, ensuring that everyone feels included, valued, safe and loved.It's an illuminating conversation and we'll hear it on this episode of the SFN Dad to Dad Podcast.Show LinksPhone – (630) 442-4031Email – rickbolle2@icloud.comLinkedIn –  https://www.linkedin.com/in/rick-bolle-6955b150/Website - https://kidsmatter2us.org/front-porch-church/Facebook – https://www.facebook.com/groups/962219779455651Special Fathers Network -SFN is a dad to dad mentoring program for fathers raising children with special needs. Many of the 800+ SFN Mentor Fathers, who are raising kids with special needs, have said: "I wish there was something like this when we first received our child's diagnosis. I felt so isolated.  There was no one within my family, at work, at church or within my friend group who understood or could relate to what I was going through."SFN Mentor Fathers share their experiences with younger dads closer to the beginning of their journey raising a child with the same or similar special needs. The SFN Mentor Fathers do NOT offer legal or medical advice, that is what lawyers and doctors do. They simply share their experiences and how they have made the most of challenging situations.Check out the 21CD YouTube Channel with dozens of videos on topics relevant to dads raising children with special needs - https://www.youtube.com/channel/UCzDFCvQimWNEb158ll6Q4cA/videosPlease support the SFN. Click here to donate: https://21stcenturydads.org/donate/Special Fathers Network: https://21stcenturydads.org/  SFN Mastermind Group - https://21stcenturydads.org/sfn-mastermind-group/

David Galán, analista de Bolsa General, analiza las acciones de Acciona, Elecnor, Thermo Fisher Scientific, Comfort Systems o Tubacex

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über Nvidias neuen KI-Billigchip, Hoffen auf das Pharma-Revival und was diese Woche sonst noch wichtig wird. Außerdem geht es um VanEck Uranium and Nuclear Technologies ETF (WKN: A3D47K), Uranium Energy, Oklo, Nuscale, Health Care Select Sector SPDR (WKN: A14QB2), CVS Health, United Health Group, Eli Lilly, Cigna, Danaher, Thermo Fisher Scientific sowie Gilead, Sandoz, J&J, Roche, Sanofi, VanEck Quantum Computing ETF (WKN: A418QM) Google, IBM, Microsoft, Sony, Boeing, Honeywell, IonQ, Rigetti und D-Wave. Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Today's Full Court Finance at Zacks dives into two beaten-down S&P 500 stocks—Thermo Fisher Scientific and Lululemon—to consider buying now for at least 40% upside. (0:15) - Stock Market Update: Everything You Need To Know In The New Bull Market  (5:00) - Buy These Two S&P 500 Stocks On The Dip For Long-Term Returns? (18:10) - Episode Roundup: Podcast@Zacks.com

Wes's journey from a paper route at 12 years old to becoming a leader in biotech and healthcare is a testament to his extraordinary work ethic, sharp analytical skills, and dedication to making impactful changes. His story highlights how early challenges can fuel transformative success, blending engineering, marketing, and data to drive innovation in healthcare.00:09- About Wes WheelerMr. Wheeler is the Chief Executive Officer and board member of LabConnect, Inc.He has served on the board of directors of Evotec since June 2024. He previously served as president of UPS Healthcare from 2020 to 2023 and chief executive officer of its subsidiary Marken LLP from 2011 to 2019, chief executive officer, president and director of Patheon (now a Thermo Fisher Scientific company) from 2007 to 2010.

14. mai 2025 I dag er vi så heldige å ha med oss forsker Karl-Johan Malmberg i podkasten vår. Kalle, som alle kaller ham, er en pionér innen forskning på naturlige drepeceller, NK-celler, og får i år Kong Olav Vs Kreftforskningspris av Kreftforeningen for arbeidet sitt. Vi snakker om bakgrunnen hans som hematolog, hvordan han som svensk, endte opp i Norge, NK-celler og når et eventuelt behandlingsgjennombrudd kan komme, ACT-senteret og samlokaliseringen med Thermo Fisher Scientific og mye, mye mer.

What does clinical trial monitoring have in common with growing a field of corn? Amy Kroeplin (PPD™ clinical research business of Thermo Fisher Scientific), Shailesh Madel (ICON plc), and Nicole Stansbury (Premier Research) join the podcast to discuss the importance of risk-based quality management, centralized monitoring, and strategic SDV/SDR sampling strategies. They dive deeper into the unique roles of SDV and SDR, different methods of implementing SDV/SDR sampling strategies, and the industry imperative to increase centralized monitoring adoption.

Gary Falcetano, Scientific Affairs Manager for Allergy at Thermo Fisher Scientific, is a leader in allergy and autoimmune diagnostics, providing specific IgE tests and the instruments to run them. Accurately diagnosing allergies can be challenging, but specific IgE testing can help confirm the underlying causes by looking at individual allergen components for precise diagnosis. This is the first step in determining the appropriate management approach to potentially interrupt the atopic march, where allergies can progress or even be life-threatening. Gary explains, "It runs the gamut of just about anything that could potentially be an allergy disease. So I think the majority of our testing is done in both environmental allergies and food allergies. What people think about when we, especially this time of year in the US, with spring about to become a big onslaught, are environmental allergies, including pollens, grass, trees, and weeds. Also, looking at some of the indoor triggers to environmental allergies like dust mites, pets, molds, and mice is pretty key when assessing for respiratory-type symptoms. On the food side, any of a number of foods can potentially cause a patient to produce specific IgE, which is the sensitization that allows us to become allergic." "We all think of respiratory allergies as straightforward, but there's an overlap of symptoms, especially from non-allergic causes, that can cause similar symptoms. So when thinking about respiratory allergies, we think about nasal congestion, post-nasal drip, and cough. Those symptoms can all be certainly caused by allergies, but they also can be caused by non-allergic triggers. That's one of the places where diagnostic allergy testing or specific IgE testing comes in to confirm whether we're dealing with an allergy. Then, if it's an allergy, what specifically is driving the symptoms? Once we rule out allergy, we can go down a whole other diagnostic pathway for all the various causes, like non-allergic rhinitis." #ThermoFisherScientific #Allergies #AllergyTesting #ClinicalDiagnostics #PatientCare #IgETesting thermofisher.com Listen to the podcast here

Gary Falcetano, Scientific Affairs Manager for Allergy at Thermo Fisher Scientific, is a leader in allergy and autoimmune diagnostics, providing specific IgE tests and the instruments to run them. Accurately diagnosing allergies can be challenging, but specific IgE testing can help confirm the underlying causes by looking at individual allergen components for precise diagnosis. This is the first step in determining the appropriate management approach to potentially interrupt the atopic march, where allergies can progress or even be life-threatening. Gary explains, "It runs the gamut of just about anything that could potentially be an allergy disease. So I think the majority of our testing is done in both environmental allergies and food allergies. What people think about when we, especially this time of year in the US, with spring about to become a big onslaught, are environmental allergies, including pollens, grass, trees, and weeds. Also, looking at some of the indoor triggers to environmental allergies like dust mites, pets, molds, and mice is pretty key when assessing for respiratory-type symptoms. On the food side, any of a number of foods can potentially cause a patient to produce specific IgE, which is the sensitization that allows us to become allergic." "We all think of respiratory allergies as straightforward, but there's an overlap of symptoms, especially from non-allergic causes, that can cause similar symptoms. So when thinking about respiratory allergies, we think about nasal congestion, post-nasal drip, and cough. Those symptoms can all be certainly caused by allergies, but they also can be caused by non-allergic triggers. That's one of the places where diagnostic allergy testing or specific IgE testing comes in to confirm whether we're dealing with an allergy. Then, if it's an allergy, what specifically is driving the symptoms? Once we rule out allergy, we can go down a whole other diagnostic pathway for all the various causes, like non-allergic rhinitis." #ThermoFisherScientific #Allergies #AllergyTesting #ClinicalDiagnostics #PatientCare #IgETesting thermofisher.com Download the transcript here

ACRO's Good Clinical Podcast is back for season 3! To kick off the season, host Sophia McLeod is joined by Clare Campbell-Cooper (Global Head, Digital Health and Innovation, Fortrea) and Michael J. Cohen (Sr. Director, Lead, Environmental Sustainability, PPD™ clinical research business of Thermo Fisher Scientific) to discuss the continued evolution of environmental sustainability in clinical research. They dive deeper into how the clinical research industry can use renewable energy to help meet environmental goals, the importance of promoting more environmentally sustainable shipping and logistics practices, and how our industry can decentralize trial elements responsibly to minimize the environmental impact of the clinical supply chain.

Laboratories use up to ten times the energy of typical office spaces, making sustainability in science a pressing issue. In this episode of Science with a Twist, host Terri Somers speaks with James Connelly, CEO of My Green Lab, and Alyssa Caddle, Senior Director of Global Sustainability at Thermo Fisher Scientific, about steps laboratories can take to reduce their environmental impact. From energy-efficient cold storage to sustainable lab products, James and Alyssa discuss how the life science industry is evolving to meet ambitious climate goals. 

In this episode of Deep Dives with Iman, Iman Mossavat interviews Dr. Remco Schoenmakers, Senior Director and AI Strategy Lead at Thermo Fisher Scientific. Dr. Schoenmakers discusses his journey in AI, from his early days in astrophysics to leading AI strategy for the Electron Microscopy business. He shares insights on how AI is transforming the scientific landscape, emphasizing that it is a tool to enhance, not replace, human expertise. With his vast experience, Dr. Schoenmakers also addresses the growing influence of AI in workplaces, offering perspectives on the role of future generations of scientists. 2025, Radio 4 Brainport, Eindhoven

With prior Mol Bio Minutes episodes covering DNA form migration and staining considerations for nucleic acid gel electrophoresis, we tie it all together with this great set of overall tips, tricks and resources for the topic. Anyone that's ever run a gel has undoubtedly produced gels with smeared, faint or poorly separated bands. What causes these and how can you avoid them?  Well, Aistė Polikaitytė, Scientist at Thermo Fisher Scientific is here to cover the likely causes and troubleshooting tips to help avoid the most common gel issues. She touches on how much sample to load, the importance of reagent selection, gel preparation, separation conditions, staining, as well as purification and contamination considerations. Helpful resource links mentioned in this episode:Selection guide for electrophoresis dyes and buffersLearn how using precast E-Gel agarose gel can help avoid common issuesA helpful troubleshooting guide for nucleic acid gel electrophoresisView an on-demand webinar covering these topics in more detail Subscribe to get future episodes as they drop and if you like what you're hearing we hope you'll share a review or recommend the series to a colleague.  Visit the Invitrogen School of Molecular Biology to access helpful molecular biology resources and educational content, and please share this resource with anyone you know working in molecular biology. For Research Use Only. Not for use in diagnostic procedures.

This episode discusses the growing threat of sepsis, a life-threatening condition caused by the body's overwhelming response to an infection. It explores the connection between the rise in sepsis cases and the increasing problem of antibiotic resistance, highlighting the importance of effective diagnostic tools and antibiotic stewardship programs in combating this public health challenge.   About Our Speaker: Dr. Mike Broyles With more than 30 years of experience as a hospital pharmacy and laboratory director, Dr. Broyles is a leading expert on sepsis and the clinical use of drugs with a focus on antimicrobial stewardship. Prior to joining Thermo Fisher Scientific, Dr. Broyles was a consultant for over 25 years working with a large independent hospital network as pharmacy advisor chairman focused on developing and implementing hospital-wide clinical initiatives. Dr. Broyles has worked passionately throughout his career to define effective protocols and decision support processes in patient management and the use of diagnostic technology to help clinicians improve outcomes through better clinical care.

Troy Lamb from the Utah Department of Workforce Services talks about job openings at Intermountain Healthcare and Thermo Fisher Scientific.

In this episode of Technovation, host Peter High speaks with Ryan Snyder, Senior VP & CIO of Thermo Fisher Scientific, a $40 billion global leader in life sciences. Ryan shares how AI, automation, and data strategy are driving digital transformation—optimizing operations, accelerating clinical trials, and enhancing customer experiences.

As the organ transplant list continues to grow, experts in the transplant diagnostics industry are looking for ways to address the supply and demand challenges within the field. New tactics, like retransplantation and xenotransplantation, and new testing methods, such as HLA testing and transplant diagnostics, are being explored to boost transplant success rates and ensure more patients get the lifesaving transplants they need. As President of Thermo Fisher Scientific's transplant diagnostics division, Tina Liedtky is at the cutting edge of meeting this challenge. She's also passionate about addressing health equity issues, such as ingrained biases regarding gender and race, to help bridge the transplantation gap.Tina joined Meg for a fascinating discussion about the future of transplantation, closing 'the gap', and Thermo Fisher's recent award. Qualio website:https://www.qualio.com/ Previous episodes:https://www.qualio.com/from-lab-to-launch-podcast Apply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8 Music by keldez

Nicholas Capman of The FDA Group welcomes David Festa, Director of Corporate Quality at Thermo Fisher Scientific, to explore whether pharmaceutical and medical device companies are auditing suppliers too frequently and with the right personnel.With over 25 years of experience in quality management and oversight of tens of thousands of suppliers, David advocates for a more strategic approach that balances quality, compliance, and business needs through "exception-based" auditing.Rather than rigidly adhering to calendar-based audit schedules, David suggests companies should assess suppliers based on performance metrics, risk factors, and the criticality of materials they provide. He challenges the industry norm that every supplier must be visited at predetermined intervals, arguing that well-performing suppliers with stable processes may not require frequent on-site visits.David emphasizes the importance of matching auditor expertise with supplier categories. For example, an auditor with deep knowledge of plastics manufacturing will provide far more valuable insights when evaluating a plastics supplier than someone familiar only with general standards. This targeted approach has helped Thermo Fisher predict quality issues and decrease the percentage of poor-performing suppliers.The conversation explores how post-pandemic practices have evolved, with companies developing more harmonized approaches to global auditing and implementing centralized audit portals. David also introduces the concept of a "supplier pricing index" that quantifies the true cost of poor quality, providing a more accurate picture of supplier value than piece price alone.While ISO certifications provide a foundation for quality systems, David cautions against over-reliance on certifications or imposing unnecessary standards on suppliers. The most effective approach focuses on whether suppliers can maintain control of their manufacturing processes and consistently deliver quality products, regardless of certification status.For companies looking to optimize their supplier quality programs, the key is putting the right people in the right places, implementing quantifiable metrics, and taking a holistic view that integrates quality with other business functions.____The FDA Group helps life science organizations rapidly access the industry's best consultants, contractors, and candidates. Our resources assist in every stage of the product lifecycle, from clinical development to commercialization, with a focus in Quality Assurance, Regulatory Affairs, and Clinical Operations. For project or resource needs, visit: ⁠⁠⁠⁠⁠⁠thefdagroup.com⁠⁠⁠⁠⁠⁠.

You can run the perfect agarose gel to separate your nucleic acid fragments but if you don't stain and image the gel properly, it's all for not. In this second installment of Mol Bio Minutes we take a look at the staining considerations for nucleic acid gel electrophoresis with Paulius Palaima, Product Manager at Thermo Fisher Scientific. He covers the range of stains and staining approaches available while calling out pros, cons and considerations for each. How these recommendations change, depending on your sample, is also covered in this approachable but informative episode. Helpful resource links mentioned in this episode:A helpful DNA stain selection guideRNA stain options and detailsEffects of dyes on gel electrophoresis properties Subscribe to get future episodes as they drop and if you like what you're hearing we hope you'll share a review or recommend the series to a colleague.  Visit the Invitrogen School of Molecular Biology to access helpful molecular biology resources and educational content, and please share this resource with anyone you know working in molecular biology. For Research Use Only. Not for use in diagnostic procedures.

Following lower closes yesterday, S&P futures are still pointing to a softer open today, down (0.13%). Asian markets were firmly lower on Tuesday, with the Nikkei dropping (1.4%) as it hit the lower end of its five-month trading range. The Hang Seng fell (1.3%) but saw mid-morning dip buying in tech stocks, supported by mainland inflows. European markets opened mixed but are edging higher, while bond yields are finding support amid safe-haven buying. Companies Mentioned: Apple, Thermo Fisher Scientific, Solventum Corp, Starbucks

Send Jay comments via textJoin us in this enlightening episode as we embark on a profound journey of self-discovery with my guest, Nicoa Dunne from Life by Design and the Coffee with Nicoa podcast. Nicoa shares her courageous transition from feeling unfulfilled in a corporate HR executive role to becoming an Life & Executive Coach, redefining her life on her own terms in her empty nest life.Throughout our conversation, Nicoa reveals her personal story of navigating challenges such as panic attacks and societal pressures and emphasizing the importance of aligning life with true values. We dive into the complexities of identity transition, discussing significant life changes, including empty nesting, divorce, and career shifts, while shedding light on the accompanying feelings of guilt and the quest for self-rediscovery.Highlights:Explore the journey from corporate success to life coaching and authorship.Discover the transformative concept of the "six-word story" for redefining self-identity.Understand the emotional landscape of navigating identity shifts after children leave home.Learn practical strategies for journaling and self-dialogue to gain clarity.Gain insights on managing energy and shifting perspectives for a more fulfilling life.Key Takeaways:Embrace change and prioritize personal happiness while navigating life's transitions.Recognize the significance of self-awareness and acceptance in enhancing relationships.Shift your mindset to view life as happening for you, rather than to you, to foster fulfillment.Challenge societal notions of success and create a life that resonates with your personal values.We encourage listeners to embrace their unique journeys, allowing space to grieve past identities while celebrating the freedom to design a life that truly reflects who they are. Tune in for inspiration, insightful discussions, and practical advice to empower your self-discovery journey!Nicoa Dunne BioNicoa is a seasoned guide with 20+ years as a Human Resources Executive with General Electric, Thermo Fisher Scientific, and Allscripts. She has excelled as a certified coach through the Newfield Network and the Institute for Professional Excellence in Coaching all while proudly parenting three kids! Over the years, she has consulted 100s of business leaders and top executives from Fortune 100 companies across the globe, shaping more effective, satisfied leaders through the seven levels of energy leadership, revealingFREE WORKBOOK3 Steps to Loving Your Empty Nest Life ENJOY THE SHOW?Don't miss an episode, subscribe via Apple Podcasts or follow on Spotify and many more. LOVE THE SHOW?Get your THIS EMPTY NEST LIFE swagReview us on Love the Podcast, Apple Podcasts, or Spotify -- reviews and ratings help others find us and we'd appreciate your support greatly.CONNECT WITH JAYEmail, LinkedIn, Instagram, or TikTok

Agarose gel electrophoresis is a staple method in almost all biology and biochemistry lab where separation and analysis of nucleic acids is needed. In this Mol Bio Minutes mini episode Augustė Užuotaitė, Scientist III at Thermo Fisher Scientific, covers the basics of electrophoresis with a spotlight on how different forms of DNA migrate differently in agarose gel electrophoresis.In less than 10 quick minutes, you'll learn about the many factors that affect DNA migration rate. Augustė reviews how DNA size, sequence, and conformation all affect migration rate, and she gives some beautifully simple examples to help it all make sense. Helpful resource links mentioned in this episode:Nucleic acid gel electrophoresis – summarized in 5 easy stepsFive important considerations for the nucleic acid gel electrophoresis Subscribe to get future episodes as they drop and if you like what you're hearing we hope you'll share a review or recommend the series to a colleague.  Visit the Invitrogen School of Molecular Biology to access helpful molecular biology resources and educational content, and please share this resource with anyone you know working in molecular biology. For Research Use Only. Not for use in diagnostic procedures.

Mike Armstrong and Paul Lane discuss Trump's desire to fix the housing affordability crisis. The IRA expands its free tax filling option. Egg prices are high. They will likely go higher. Return-to-office policies are 'creeping up.' Many workers would rather quit. Why you should be wary of the unlimited vacation perk. Paul LaMonica, Barron's, joins the show to chat about Thermo Fisher Scientific and well they are positioned in case RFK Jr shakes up the medical industry.

Spirit Switchboard Episode #91 Jan. 17th, 2025 Topic: Activating Our 12 Stranded DNA Guest: Ruslana Remennikova This week on Spirit Switchboard, I am joined by sound healer and former corporate scientist Ruslana Remennikova. Can we truly transform our DNA for profound personal healing and spiritual awakening? In her latest book, "Activating Our 12 Stranded DNA: Secrets of Dodecahedral DNA for Completing Our Human Evolution," Ruslana reveals ten frequencies that resonate with DNA, along with techniques and meditations designed to activate your 12-stranded DNA for emotional and physical healing, ancestral healing, and conscious evolution. Guest Bio: Ruslana Remennikova is a former research scientist for the Fortune 100 – ranked company Thermo Fisher Scientific where she worked with vaccine sciences. In a 2016 leap of faith for a more meaningful life, she left the world of corporate science to later open a sound medicine practice while writing her first book. Additionally, Ruslana has facilitated over 200 transformative sound sessions. She is the founder of Songbird Science, a research and education enrichment provider exploring frequency and consciousness. Guest Links: Website: https://ruslanaremennikova.com/ Instgram: https://www.instagram.com/ruslana.remennikova/ Youtube: https://www.youtube.com/channel/UCbcwY8WEhaePuRoXqoV_bdA Inner Traditions: https://www.innertraditions.com/activating-our-12-stranded-dna Message from Kerrilynn: I want to hear from you! I want to hear about your ghost stories, paranormal adventures and occurrences. I would also love your show suggestions to cover in the future. Email me at kerrilynn.shellhorn@gmail.com. If you enjoy the content on the channel please live, subscribe and share. My deepest gratitude to you all! A formal disclaimer: The opinions and information presented or expressed by guests on Spirit Switchboard are not necessarily those of the Host or the United Public Radio Network/UFO Paranormal Radio Network and its producers. As always Spirit Switchboard strives to hold space for open, respectful dialogue with show guests and listeners. Host links: http://www.kerrilynnshellhorn.com https://www.instagram.com/theoriginalkerrilynnshellhorn.com/ https://www.facebook.com/kerrilynn.shellhorn https://www.youtube.com/@kerrilynn-SpiritSwitchboard/streams

What compels someone to leave the stability and prestige of a CFO role at IBM Europe for the unknowns of a 16-person startup? For Josh Geballe, it was the thrill of challenge and the promise of making a real impact. His 30-year career reflects this relentless pursuit of meaningful work. From managing finance at IBM to leading Core Informatics as CEO, from VP at Thermo Fisher Scientific to COO of Connecticut's COVID-19 response, Josh has consistently embraced complex problems with courage and determination. Currently, as Managing Director at Yale Ventures, he is creating pathways for entrepreneurs and innovators, all while continuing to push boundaries. Josh's journey shows that taking risks and following your instincts can redefine not just a career but an entire industry. Key Highlights of Our Interview: Big Corporate to Small Chaos “Jumping from one of the world's biggest companies to a 16-person startup was like going from a luxury cruise to a whitewater raft. Every day brought new challenges—chasing customers, closing funding rounds, and ensuring payroll didn't bounce. It wasn't for the faint-hearted, but I embraced the chaos because it was exactly the dynamic challenge I craved.” The Two Engines of Growth: Impact and Challenge “My career choices boil down to two drivers: solving meaningful problems that make a positive impact on society and embracing challenges that push me to grow personally and professionally. It's how I've turned a seemingly unusual career journey into a purposeful adventure.” Gut Instinct: The Silent Strategist “For all the logic and strategy in career decisions, sometimes it comes down to a gut feeling. Big moves in my career have often hinged on an instinctual ‘yes' or ‘no,' and I've been fortunate that those instincts have steered me right—no regrets, just leaps of faith.” Bridging the Academic-Entrepreneurial Divide “Helping brilliant minds shift from academic jargon to investor-friendly pitches is a key part of the role. It's all about connecting ideas to resources—whether that's investors, teammates, or future opportunities. And for students? It's about teaching them to innovate and navigate their career paths, with or without a startup dream right now.” _________________________ Connect with Us: Host: Vince Chan | Guest: Josh Geballe ______________________ Chief Change Officer: Make Change Ambitiously. Experiential Human Intelligence for Growth Progressives Global Top 3% Podcast on Listen Notes World's #1 Career Podcast on Apple Top 1: US, CA, MX, IE, HU, AT, CH, FI, JP 3+ Millions Downloads 80+ Countries

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Luca Quagliata, Vice President and Global Head of Medical and Scientific Affairs at Thermo Fisher Scientific, a company committed to advancing precision medicine, for a conversation on this space and a new frontier of biomarkers. Quagliata discusses Thermo Fisher's ongoing collaboration with EVERSANA, pharmaphorum's parent company, and that collaboration's investigation of the impact of utilising electronic health record (EHR) data in haematological cancers to support the company's value proposition for ultra-fast next generation sequencing (NGS) with oncomine myeloid solutions. That included a presentation at Frontiers Health 2024, in Berlin, in the deep dive, ‘Overcoming data linkage barriers with tokenization technology: RWE on the use of targeted therapy and its impact on survival in blood malignancies' – presented alongside Dr Pierantonio Russo, Corporate Chief Medical Officer at EVERSANA.

Peter Dickstein is a 35-year business leader (Founder, CEO, CFO, and strategy advisor). He is Founder of ShadyPower Technologies, developer of a proprietary, patent-pending IOT technology platform for climate-sustainable, enhanced comfort outdoor work and living. He is Co-Founder of TAPS, a machine-learning consultancy focused on sales lead optimization and churn prevention. He is Chairman (Emeritus) and Co-Founder of Solful (www.solful.com), a California-based branded destination cannabis dispensary company and a guest lecturer at universities including the Haas School of Business at UC Berkeley. He has served in CEO, Chairman, and other C-Suite roles for IOT, SAAS, cleantech, and travel insurance companies. In 1999 Peter founded and served as CEO of eProsper, Inc. (ultimately acquired by Morgan Stanley in 2018 for $900MM) whose patented, SAAS capitalization management system (“CapMx”) became the industry gold standard in the early 2000s and is used today by more than 6,000 venture-funded companies and their corporate law firms. Peter served as CFO for several medical device and technology companies including TruMed Systems, Inc., EndoTex Interventional Systems (acquired by Boston Scientific) and Atrionix (acquired by Johnson & Johnson). He was an EIR at Los Alamos National Laboratory where he identified and helped commercialize technology including Acoustic Cytometry Systems (acquired by Thermo Fisher Scientific) and architected the Los Alamos Venture Acceleration Fund. In the early 90s Peter negotiated a $500MM vendor financing facility for Pyxis Corporation (ultimately acquired by Becton Dickinson for $12BB) with GE Capital that rapidly accelerated Pyxis' market penetration and provided non-dilutive growth capital in lieu of equity. In addition to his general management roles, Peter has initiated, organized, negotiated, and completed numerous equity, debt, and M&A transactions with angel, institutional and strategic investors, and lenders. He has managed functional areas including product development and engineering, sales, service, finance and administration, and external relationships with investors, contract manufacturers, investment bankers, banks, attorneys, and auditors. Peter has served on the boards of Friends of the Urban Forest, the San Francisco Day School, and multiple companies. He is a dual citizen of the United States and Germany. He holds a B.A. from the University of Pennsylvania and a M.B.A. from The Wharton School.

Before founding inGENEious RX Incorporated, a boutique pharmacogenomics consulting firm, Dr. Winslow directed pharmacy business operations and clinical pharmacy programs in retail, hospital, long-term care, and public health pharmacies for Walmart Stores, Community Health Systems, Neil Medical Group, and the North Carolina Department of Health and Human Services. Since founding inGENEious RX over eleven years ago, Dr. Winslow has worked with numerous distinguished vendors in the pharmacogenomics industry including Translational Software, Admera Health, Genemarkers, National Association of Chain Drug Stores, Kentucky Teachers' Retirement System, GenXys, and Thermo Fisher Scientific.  A sought-after pharmacogenomics subject matter expert, Dr. Winslow, has authored PGx payer databases and billing and coding algorithms and served Mintz Law as the expert medical necessity reviewer of Medicare PGx claims. She is an authority in pharmacogenomics access and reimbursement and specializes in business strategy consulting for pharmacogenomics stakeholders.   Dr. Winslow is an Advanced Pharmacy Practice Experience preceptor for Manchester University School of Pharmacy PharmD/Masters in PGx students and a registered trainer for the University of Pittsburgh's Test2Learn (TM) Community PGx Certificate Program. Dr. Winslow is a member of the Clinical Pharmacogenetics Implementation Consortium, the NCPDP PGx Task Force, and the Get the Medications Right Institute.  In 2021, Welp Magazine recognized Dr. Winslow's podcast, the PGx for Pharmacists Podcast, as the world's ninth most listened-to genetics podcast. Her podcast shares the top 20 most listened-to genomics podcast list with genomics podcasts created by such notable podcasters as the National Cancer Institute and the American Heart Association. The Pharmacy Podcast Network recognized Dr. Winslow in 2021 as a Top 50 pharmacy influencer. Entities frequently recruit Dr. Winslow to present PGx topics. She has presented at conferences for the National Association of Boards of Pharmacy, the National Association of Specialty Pharmacy, the Inovalon Customer Congress, and the Association for Molecular Pathology and on the Labroots' and Precision Medicine Institute's platforms.  Dr. Winslow earned her Bachelor of Science in Biology and Doctor of Clinical Pharmacy degrees from Campbell University. Lexi Wensel is a 2024 Manchester University School of Pharmacy graduate where she earned her Doctorate in Pharmacy and Masters in Pharmacogenomics. When this episode was recorded in April 2024, Lexi was completing an advanced pharmacy practice experience with Dr. Becky Winslow, preceptor for Manchester University School of Pharmacy. While studying to become a pharmacist, Lexi gained practical clinical pharmacy experience while working as a pharmacy intern at both Meijer pharmacy and Marion Health Hospital.   Beyond her academic and professional endeavors, Lexi is deeply committed to giving back to the community. She serves as a board member for an organization called Guatemala Family Development where she contributed to initiatives aimed at improving healthcare access and promoting wellness in underserved communities. At the time this episode was recorded, Lexi was completing an advanced pharmacy practice experience with Dr. Becky Winslow, preceptor for Manchester University School of Pharmacy.  Dr. Mary Weissman is a clinical pharmacogenomics specialist and inGENEious RX Incorporated consultant. Since earning her Doctor of Pharmacy degree from Arnold and Marie Schwartz College of Pharmacy and completing a two-year pharmacogenomics fellowship in a clinical laboratory's medical affairs department, Dr. Weissman has applied her pharmacogenomics expertise in clinical diagnostic laboratories. At those laboratories, she has scientifically, and clinically supported pharmacogenomics stakeholders to increase clinical pharmacogenomics implementation into clinical settings. Holding titles such as clinical scientist, she has authored and developed medical content to educate healthcare providers and patients about pharmacogenomics and authored clinical decision support tools prescribers use to leverage pharmacogenomic insights in medication therapy management. Through educational trainings, white papers, presentations, and webinars, she has clarified pharmacogenomics' complexities and helped move pharmacogenomics toward a standard of care.  

Before founding inGENEious RX Incorporated, a boutique pharmacogenomics consulting firm, Dr. Winslow directed pharmacy business operations and clinical pharmacy programs in retail, hospital, long-term care, and public health pharmacies for Walmart Stores, Community Health Systems, Neil Medical Group, and the North Carolina Department of Health and Human Services. Since founding inGENEious RX over eleven years ago, Dr. Winslow has worked with numerous distinguished vendors in the pharmacogenomics industry including Translational Software, Admera Health, Genemarkers, National Association of Chain Drug Stores, Kentucky Teachers' Retirement System, GenXys, and Thermo Fisher Scientific.  A sought-after pharmacogenomics subject matter expert, Dr. Winslow, has authored PGx payer databases and billing and coding algorithms and served Mintz Law as the expert medical necessity reviewer of Medicare PGx claims. She is an authority in pharmacogenomics access and reimbursement and specializes in business strategy consulting for pharmacogenomics stakeholders.   Dr. Winslow is an Advanced Pharmacy Practice Experience preceptor for Manchester University School of Pharmacy PharmD/Masters in PGx students and a registered trainer for the University of Pittsburgh's Test2Learn (TM) Community PGx Certificate Program. Dr. Winslow is a member of the Clinical Pharmacogenetics Implementation Consortium, the NCPDP PGx Task Force, and the Get the Medications Right Institute.  In 2021, Welp Magazine recognized Dr. Winslow's podcast, the PGx for Pharmacists Podcast, as the world's ninth most listened-to genetics podcast. Her podcast shares the top 20 most listened-to genomics podcast list with genomics podcasts created by such notable podcasters as the National Cancer Institute and the American Heart Association. The Pharmacy Podcast Network recognized Dr. Winslow in 2021 as a Top 50 pharmacy influencer. Entities frequently recruit Dr. Winslow to present PGx topics. She has presented at conferences for the National Association of Boards of Pharmacy, the National Association of Specialty Pharmacy, the Inovalon Customer Congress, and the Association for Molecular Pathology and on the Labroots' and Precision Medicine Institute's platforms.  Dr. Winslow earned her Bachelor of Science in Biology and Doctor of Clinical Pharmacy degrees from Campbell University. Lexi Wensel is a 2024 Manchester University School of Pharmacy graduate where she earned her Doctorate in Pharmacy and Masters in Pharmacogenomics. When this episode was recorded in April 2024, Lexi was completing an advanced pharmacy practice experience with Dr. Becky Winslow, preceptor for Manchester University School of Pharmacy. While studying to become a pharmacist, Lexi gained practical clinical pharmacy experience while working as a pharmacy intern at both Meijer pharmacy and Marion Health Hospital.   Beyond her academic and professional endeavors, Lexi is deeply committed to giving back to the community. She serves as a board member for an organization called Guatemala Family Development where she contributed to initiatives aimed at improving healthcare access and promoting wellness in underserved communities. At the time this episode was recorded, Lexi was completing an advanced pharmacy practice experience with Dr. Becky Winslow, preceptor for Manchester University School of Pharmacy.  Dr. Mary Weissman is a clinical pharmacogenomics specialist and inGENEious RX Incorporated consultant. Since earning her Doctor of Pharmacy degree from Arnold and Marie Schwartz College of Pharmacy and completing a two-year pharmacogenomics fellowship in a clinical laboratory's medical affairs department, Dr. Weissman has applied her pharmacogenomics expertise in clinical diagnostic laboratories. At those laboratories, she has scientifically, and clinically supported pharmacogenomics stakeholders to increase clinical pharmacogenomics implementation into clinical settings. Holding titles such as clinical scientist, she has authored and developed medical content to educate healthcare providers and patients about pharmacogenomics and authored clinical decision support tools prescribers use to leverage pharmacogenomic insights in medication therapy management. Through educational trainings, white papers, presentations, and webinars, she has clarified pharmacogenomics' complexities and helped move pharmacogenomics toward a standard of care.  

In this podcast, we spoke with Isha Dey, Senior Scientist, Cell Biology R&D, at Thermo Fisher Scientific about the challenges researchers face in selecting appropriate cell culture conditions due to variability in cell lines, lack of standardized protocols, and inconsistent reagent quality. Thermo Fisher Scientific's new Cell Culture Select Tool was developed to address these challenges by providing specific recommendations for media, FBS, and cultureware for over 150 cell lines, backed by extensive R&D data. Understanding the Challenges in Cell Culture Selection Thermo Fisher Scientific's new Cell Culture Select Tool addresses a persistent challenge in laboratory science: identifying the appropriate cell culture conditions and selecting the right media, supplements, and reagents for different cell lines. The process is complicated by factors like cell line variability, lack of standardized protocols, and inconsistent reagent quality. These issues can introduce variability and impact experimental results, posing a challenge for scientists across labs. “Different cell lines have unique requirements,” explained Isha. “It's challenging to pinpoint optimal culture conditions due to variability in cell line responses. Additionally, there isn't always a standardized protocol across labs or comprehensive information on specific culturing needs. This can make it difficult to select the most appropriate media, supplements, and other materials.” Ensuring a consistent supply of high-quality products is essential for reproducibility in experiments. Thermo Fisher Scientific's trusted brands, such as Gibco, Nunc, and Invitrogen, are known for their quality, which is critical for minimizing variability in experimental readouts. The Inspiration Behind the Cell Culture Select Tool The idea for the Cell Culture Select Tool originated from an update to Thermo Fisher Scientific's online technical reference library. Previously, the website listed recommended media types segmented by cell line culture methods—adherent, semi-adherent, or suspension. While helpful, this list was lengthy and lacked interactive functionality. Isha said, “We realized that we could streamline this information into a user-friendly tool”. “In our R&D labs, we culture over 150 cell lines using various media, supplements, and equipment. By making this data accessible to other researchers through an interactive tool, we hoped to eliminate the guesswork and enable reproducible cell culture success.” The tool now provides recommendations for specific media, supplements, and cultureware for culturing, passaging, and freezing over 150 cell lines. With in-house data supporting 75% of these lines, researchers gain access to the resources and insights gathered from Thermo Fisher's extensive R&D experience. Selecting Cell Lines for the Tool The team started with cell lines listed in their technical reference webpage and expanded the list based on the lines frequently cultured in their R&D labs. These labs conduct heavy cell culture work for various applications, including media development, fluorescence imaging, Western blotting, flow cytometry, transfection, transduction studies, and more. “We wanted to make our R&D data available to researchers for convenience,” shared Isha. “This effort involved many scientists across R&D sites who contributed data and images showing how each cell line appears in recommended media.” Quality and Verification in Thermo Fisher's Labs The tool's data is backed by rigorous testing in Thermo Fisher's R&D labs. Cells are grown in their respective media, culture plastics, and consumables over multiple passages to ensure accuracy. For cancer cell lines, STR profiling and mycoplasma testing are conducted regularly, while stem cell cultures are assessed for pluripotency and purity using imaging and flow cytometry. “Representative images of cell lines, captured using our EVOS imaging system,

The statistics of Poisson distributions can seem complex at first but are simpler than you think, which is important to know given their relevance to digital PCR. In short, they dictate the confidence you can have in the absolute quantification provided by dPCR. Dr. Dave Bauer, Thermo Fisher Scientific's very own dPCR Product Applications Specialist and statistics whiz, joins us once again for this short-but-sweet episode that's a must hear for those working with rare, or low-abundance PCR targets. Dave and the hosts talk about applications like cancer research where these types of samples are common, and then get into the details of how the Applied Biosystems QuantStudio Absolute Q Digital PCR System works to provide elegantly simple technologies like false positive rejection, background subtraction, low dead volume microfluidic array plates, and a master mix with chamber loading dye. Join us to learn what each of these are all about and how they help to provide confidence and reliability in results that matter for your precious samples. Visit the Absolute Gene-ius pageto learn more about the guests, the hosts, and the Applied Biosystems QuantStudio Absolute Q Digital PCR System. 

Earlier this year, Thermo Fisher Scientific opened its first clinical trial Innovation Lab in Center Valley, Pa., designed to foster a culture of collaboration by providing a dedicated space for industry partners to come together, share ideas and co-create solutions for the industry's biggest challenges. The global clinical trial market was valued at over $80 billion in 2023, and that's projected to grow by 6.5% every year until 2030. But alleviating innovation silos is the only way to move the clinical trial industry forward and tackle its current challenges. And it's here that Senior Director of Innovation & Program Management Sarah Englert's mission is focused...https://www.linkedin.com/in/sarah-blake-englert-70557421/https://www.thermofisher.com/us/en/home.html Qualio website:https://www.qualio.com/ Previous episodes:https://www.qualio.com/from-lab-to-launch-podcast Apply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8 Music by keldez

Women in Chemical's interviews Nicky Burbidge, VP/GM Fine Chemical Products  at Thermo Fisher Scientific, for Woman of the Week 10/07/2024.

Modern science, especially in the genetic and molecular biology spaces, generate vast amounts of data, and require vast amounts of data to be generated for thorough analysis. For example, finding a rare gene mutation such as BCR-ABL as a biomarker for chronic myeloid leukemia is like searching for a needle in a haystack. For a situation like this, dPCR is an ideal method, but high-throughput automation is also needed.Dr. Clarence Lee, Senior Product Manger at Thermo Fisher Scientific, tells how the QuantStudio™ Absolute Q™ AutoRun dPCR suite helps make the benefits of digital PCR available in an easy-to-use high-throughput system. The conversation covers how automation benefits are provided by MAP16 plates, system software, and the AutoRun plate hotel and loading robot. Clarence also talks about customer applications where he sees automation like this being applied to innovate and drive science forward. In the career corner portion, we learn about Clarence's journey from chemist and biophysicist, to roles in industry and his current role as a product manager. He shares what he loves most about his job and what he's most proud of over his career that has spanned several diverse roles. Visit the Absolute Gene-ius pageto learn more about the guests, the hosts, and the Applied Biosystems QuantStudio Absolute Q Digital PCR System. 

A marketing technology company that provides essential marketing and salessolutions for businesses of all sizes. On a mission to help their customersachieve their mission, Banzai enables companies of all sizes to target, engage,and measure both new and existing customers more effectively. Banzai customersinclude Square, Hewlett Packard Enterprise, Thermo Fisher Scientific,Thinkific, Doodle and ActiveCampaign, among thousands of others.

Ce vendredi 6 septembre, Louis de Montalembert, président de Pléiade AM, et Pascale Seivy, directrice commerciale Banque Privée France du Groupe Lombard Odier, se sont penchés sur les titres : Visa, Salesforce, ASML, Adyen, Sika, Straumann, Thermo Fisher Scientific, Microsoft, Infineon, Alphabet, Richemont, Snowflake, Bill.com, Monday.com, Elastic, MongoDB, GitLab, Procore, et Braze, dans On achète ou on vend ? dans l'émission C'est Votre Argent présentée par Marc Fiorentino. C'est Votre Argent est à voir ou écouter le vendredi sur BFM Business.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Biopharma news on August 21, 2024 saw changes in Biomarin's C-suite, with Greg Friberg and James Sabry taking over R&D and business development. BridgeBio launched GondolaBio for rare disease drug programs, while Regeneron faced FDA setbacks for a myeloma drug. Avidity and Kymera raised funds, Walgreens partnered with Barda, and Merck licensed an antibody drug conjugate. Thermo Fisher Scientific supported oncology research with new developments in clinical trials. Overall, the industry saw leadership changes, setbacks in drug approvals, fundraising activities, partnerships, and innovations in clinical trials.A study suggested that patients on Novo Nordisk's semaglutide may have a higher risk of suicidal thoughts. The FDA denied Regeneron's drug approval for myeloma due to manufacturing issues. Lawmakers raised concerns about US biopharma companies working with the Chinese military. Novo Nordisk, Eli Lilly, and Sanofi are each focusing on different markets for their diabetes GLP-1 drugs. The impact of recent Supreme Court decisions on the healthcare and pharma industries is discussed, including challenges against regulations and reforms proposed by President Joe Biden. The uncertainty could jeopardize FDA authority and provisions in the Inflation Reduction Act, adding complexity for pharma companies.The Biosecure Act revealed gaps in domestic drug manufacturing readiness in the US. Different strategies of Novo Nordisk, Eli Lilly, and Sanofi in developing and distributing their GLP-1 drugs were highlighted. A gene therapy patent ruling raised intellectual property concerns, Genentech closed its cancer immunology group, and layoffs were reported in the industry. House lawmakers expressed worries about US biopharma companies collaborating with the Chinese military on trials. Aadi Bioscience plans to lay off 80% of its R&D staff.

Welcome, MedTech Gurus! Today, we have an incredible guest: Anupam Girdha, CEO of Ascential Technology's Medical and Life Sciences Division. Ascential is a leader in innovating and automating complex diagnostics and test processes across various industries. With over 70 years of experience and 2,300 experts worldwide, they're unstoppable in tackling mission-critical challenges and driving breakthroughs. Anupam, with key roles at Thermo Fisher Scientific, Baxter International, and ZS Associates, shares his journey of scaling manufacturing during COVID-19 and turning innovation into reality with Ascential's cutting-edge antimicrobial testing. Get ready for an electrifying episode packed with insights and innovation! 

In a session from Future of Field Service Live in Cologne, Germany, host Sarah Nicastro welcomes back Daniel Trabel, Director of Field Service EMEA at Thermo Fisher Scientific, to discuss how critical a company's talent strategy is to service today and why it demands creativity and a willingness to break free of the status quo to be successful. Daniel is a passionate and visionary leader with a strong track record in clinical diagnostics, life sciences, medical devices, and biotechnology. Before joining Thermo Fisher Scientific, he was a Service Manager at Waters Corporation in Germany South, served as a Service Engineer at Cochlear, and held various key positions at Bio-Rad Laboratories. If you enjoyed this episode, make sure to subscribe, rate, and review on Apple Podcasts, Spotify, and Google Podcasts. Also, subscribe to our newsletter right here: https://www.futureoffieldservice.com/the-insider

On this episode, Danilo Branco (Director, Central Monitoring Operations, Fortrea), Cris McDavid (Director, Global Clinical Operations, RBQM, Parexel), and Valarie McGee (Senior Director, Clinical Systems Optimization, the PPD Clinical Research Business of Thermo Fisher Scientific) join the podcast to discuss insights from 5 years of data on industry RBM/RBQM adoption collected by ACRO's RBQM Working Group has and how industry can drive further RBQM adoption.They dive deeper into ACRO's annual RBQM landscape survey findings, challenges and opportunities presented by the growth of centralized monitoring and reduced SDR/SDV, and the role that RBQM can play in the future of clinical research.

On this episode, Susan McCune, MD (VP, Pediatrics & Clinical Pharmacology, The PPD Clinical Research Business of Thermo Fisher Scientific) and Jacqui Whiteway, PhD (Senior Director & Pediatric Strategy Liaison, Center for Pediatric Clinical Development, ICON plc) join the podcast to discuss what makes pediatric clinical trials unique and how industry can make participation easier for pediatric patients and their families.They dive deeper into the role that compassion plays in designing successful trials, the importance of including pediatric patients and families in trial protocol design, and creative tools to boost patient engagement

Biomarker testing has arrived in Obstetrics. Of course, we have been using some biomarkers for years, like PAMG1 (Amnisure) and AFP+ILGFBP1 (ROM Plus) for ROM evaluation. In May 2023, the FDA cleared Thermo Fisher Scientific's maternal serum biomarker test for prediction of preeclampsia with severe features in hospitalized patients (and we have a prior episode on that). Now, as of July 9, 2024, published data has arrived for a new maternal serum biomarker ratio for the prediction of preterm birth in low-risk patients. This is the PreTRM biomarker test. This is on the path for FDA clearance. In this episode, we will review the AVERT Preterm Trial which utilizes a novel biomarker ratio using IGFBP4/SHBG. What did this study find? There some promising aspects to this, and also some striking limitations. Listen in for details!

Discover the key considerations critical to the genetic analysis for advanced therapies, including qPCR and dPCR. Don't miss expert insights from Chandler Walker, Product Manager of Digital PCR Instruments at Thermo Fisher Scientific and Janelle Hart, managing editor at Citeline.

"Be bolder sooner - it's not just about my career, it's about life in general.”  Alex Keith leads Procter & Gamble's global Beauty business: the world's 4th largest beauty company, with a $15 billion portfolio with six billion dollar brands. Alex is the only female CEO of a top 5 beauty company. Since taking leadership of P&G's Beauty portfolio in 2017, Alex has driven the sector's turnaround. As Executive Sponsor for Corporate Sustainability, Alex works alongside P&G's Chief Sustainability Officer to guide the Company's sustainability progress. She is also the company's Executive Sponsor of LGBTQ+ Equality & Inclusion. During Alex's 34 years with P&G, she has worked in Product Supply, Brand Management and General Management, spanning multiple categories across Fabric Care and Beauty, in North America, Asia, and Europe regions. In 2020, Alex was elected to Thermo Fisher Scientific's Board of Directors. A native of Pittsburgh, Pennsylvania, Alex holds a Bachelor of Science in Chemical Engineering from the University of Arizona. She lives in Geneva, Switzerland with her husband, Chris Keith.

In this solo episode of the Unscripted Podcast, host Sarah Nicastro recaps the Future of Field Service Live event in Cologne, Germany, highlighting key insights from experts at Rolls Royce Power Systems, TOMRA Recycling, Thermo Fisher Scientific, and Electrolux on industry innovation, strategic vision, talent diversity, and service transformation. The conference emphasized the importance of attracting and retaining talent while maximizing existing resources to drive efficiency and innovation in the field service industry. Sarah Nicastro is the creator of Future of Field Service and VP, Customer Engagement at IFS. After completing her bachelor's degree in psychology and then her MBA, Sarah intended to get into the non-profit sector, but life had other plans. She began her career in the media with Field Technologies magazine never even having heard the term “field service.” Expecting to grow bored quickly, she was surprised to fall in love with the layers of evolution and innovation that have kept things interesting for all these years. If you enjoyed this episode, make sure to subscribe, rate, and review on Apple Podcasts, Spotify, and Google Podcasts. Also, subscribe to our newsletter right here: https://www.futureoffieldservice.com/the-insider/  --- Send in a voice message: https://podcasters.spotify.com/pod/show/future-of-field-service/message

“ I think it's about getting clear on what your method of problem solving is. And if somebody doesn't have that, if they're not exactly sure why or how they did something, that's an easy no for you. And those people who understand from their mistakes, who can talk you through their logic, their thought process, what the algorithm they have programmed between their ears that lets people more self-aware enough and are able to get and give more feedback, we're open for more coaching and more support, and can be trusted to be left alone, not only to do the job that needs to be done, but to suss out, find and eliminate problems that you as a manager maybe didn't even know existed.”  Kolby Goodman Top Five Tips For Hiring The Best (And Most Impactful) Person For Your Team1.         Shift from skills to problem-solving2.         Clearly communicate those problems3.         Seek for understanding of actions not just knowledge4.         Dig deeper in the interview!5.         Get them excited about the challenges ahead TIME STAMP SUMMARY01:19   Problem-solving is a key trait 06:02   Problems lead to proactive minded and action-oriented people14:10   Getting real in the interview16:40   The benefits of a good hire Where to find Kolby?Website             https://www.kolbygoodman.com/consulting LinkedIn             https://www.linkedin.com/in/kolbygoodman Kolby Goodman Bio Kolby, a seasoned hiring consultant, specializes in guiding highly educated professionals—doctors, dentists, attorneys, and more—toward hiring impactful problem solvers. With a decade of experience placing over 5,000 high achievers, he has a wealth of insights into optimizing the hiring process. Featured on CBS News, LinkedIn, The Huffington Post, and more, Kolby has partnered with renowned organizations like Panasonic, Marriott Hotels, and Thermo Fisher Scientific. After a decade placing over 5,000 high achieving professionals in their dream roles, Kolby experienced the full spectrum of interview horror stories, and the countless ways well-meaning leaders were unintentionally driving away top talent. While many leaders are experts in their field, few were taught an effective recruiting, interviewing, and hiring strategy. Which has caused high turnover, poor customer experiences, and endless headache and frustration

Today, April 3, 2024, the ACOG released a clinical practice update to practice bulletin# 222 (gestational hypertension eclampsia). This is in direct response to a recent FDA approved biomarker test for risk stratification for preeclampsia. On May 19, 2023, the FDA cleared a novel biomarker serum test for the risk stratification for severe preeclampsia in hypertensive pregnant women. This clearance is the first given to any blood-based biomarker test for assessing preeclampsia risk. The company is Thermo Fisher Scientific (no disclosures). This new clinical practice update puts this test into proper perspective and gives clinicians some valuable insights of what it can, and what it cannot, do. Listen in for this “off the press” clinical practice update.